Bavarian Nordic (BAVA.CO)'s IMVANEX® Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities
5/31/2013 10:12:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
KVISTGAARD, Denmark, May 31, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced
today that the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a positive opinion recommending the
granting of a marketing authorization for IMVANEX® for active immunization
against smallpox disease for the general adult population, including people with
immunodeficiencies (people diagnosed with HIV or atopic dermatitis).
Help employers find you! Check out all the jobs and post your resume.
comments powered by